MRK Earnings Show Strength in Oncology and Animal Health, Pipeline Expansion Bolsters 2026 Outlook

Oncology and Animal Health Lead Growth Despite Mixed Vaccine Results

Merck’s latest financial results point to continued momentum in its core oncology and animal health businesses, helping to offset vaccine headwinds and restructuring costs. The company’s blockbuster immunotherapy KEYTRUDA delivered $31.7 billion in annual sales—a 7% year-over-year increase—cementing its status as a key revenue driver. Meanwhile, animal health revenue climbed 8% for the year, powered by strong demand across livestock and companion animal segments and contributions from new product launches.

Operational Strength Reflected in Financial Performance

For the full year 2025, Merck reported worldwide sales of $65.0 billion, up 1% from 2024. GAAP net income grew 7% to $18.25 billion, while non-GAAP net income rose 16% to $22.51 billion. While restructuring and acquisition-related charges weighed on margins, non-GAAP earnings per share (EPS) increased a robust 17% to $8.98. Notably, double-digit growth in non-GAAP net income and EPS highlights the company’s operational strength and the impact of strategic optimization initiatives.

Diversification Pays Off, New Launches Bring Additional Momentum

Merck’s performance was anchored by strong global uptake in earlier-stage oncology indications and continued innovation in specialty medicine. Newer products such as WINREVAIR (up 244%) and CAPVAXIVE (up 683%) showcased significant growth, with both annual sales exceeding $1 billion and $750 million, respectively. The animal health segment continued to benefit from broad demand, particularly in livestock where sales jumped 13% year-over-year.

Vaccine Franchise Faces Headwinds with Sharp GARDASIL Decline

Despite overall revenue growth, GARDASIL/GARDASIL 9 sales dropped 39% year-over-year, citing weaker demand in China and normalizing inventory patterns in Japan. This was partially offset by the successful roll-out of newer vaccines such as CAPVAXIVE and ENFLONSIA, which helped stabilize the vaccines franchise. The challenge in vaccine sales serves as a reminder of both geographic volatility and portfolio diversification importance to the broader business.

Pipeline Strength and Strategic Investments Underpin 2026 Guidance

Merck advanced its strategic objectives with 18 positive Phase 3 trial results in 2025 and over 80 Phase 3 studies underway, spanning oncology, infectious diseases, cardiometabolic, and respiratory indications. Key highlights include expanded approvals for KEYTRUDA, positive late-stage data for WINREVAIR and enlicitide, and pipeline bolstering via acquisitions of Verona Pharma and Cidara Therapeutics. The company’s agreement with the U.S. government to expand access and lower drug prices for Americans also signals a proactive approach to regulatory and reimbursement change.

2026 Outlook: Pipeline and New Launches Drive Resilience

For 2026, Merck forecasts sales between $65.5 billion and $67.0 billion and non-GAAP EPS between $5.00 and $5.15, figures that reflect a one-time significant charge relating to the Cidara acquisition. The company projects its non-GAAP gross margin to be approximately 82% and expects new launches and late-stage pipeline assets, particularly in oncology and rare diseases, to help maintain growth momentum through near-term headwinds, especially as generic and competitive pressures in other divisions persist.

Key Takeaways: Growth Engines and Innovation Remain Strong

Merck’s 2025 performance underscores the resilience of its key growth engines—oncology and animal health—while the rapid adoption of newly launched medicines and pipeline execution support optimism for the future. The rare miss in vaccine performance illustrates the value of Merck’s increasingly diversified product mix. As Merck confronts near-term margin and restructuring challenges, its ongoing clinical success and strategic investments position it well for shareholder value creation into 2026 and beyond.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI